Germline mutations in cancer-predisposition genes in patients with biliary tract cancer

The prevalence of germline mutations in patients with biliary tract carcinoma (BTC) remains unclear. Here, we investigated the prevalence and types of germline mutations in patients with BTC. We reviewed 269 patients with pathologically proven BTC and collected clinical characteristics, including medical and family histories. Additionally, we evaluated germline variants in 21 genes associated with hereditary predisposition for cancer by targeted sequencing in patients meeting ≥1 of the following criteria: 1) hereditary breast and/or ovarian cancer (HBOC) testing criteria modified for BTC, 2) Revised Bethesda Guidelines (RBGs) modified for BTC (modified RBG), 3) familial BTC criteria, or 4) young BTC criteria. Among the 269 patients, 80 met at least one criterion. Three pathogenic mutations in three patients were identified: two in BRCA2 and one in BRCA1. Among the 16 patients meeting modified HBOC testing criteria, 2 harbored germline BRCA2 mutations, and 1 harbored a germline BRCA1 mutation. However, no mutation in mismatch-repair genes were detected, despite 63 patients meeting modified RBG screening criteria and 18 qualifying as young BTC patients. We detected high prevalence of pathogenic germline mutations in BRCA1/2 and none in mismatch-repair genes in BTC patients following enrichment according to family or medical history in this study.

[1]  C. Denlinger,et al.  Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma , 2016, Cancer.

[2]  S. Hamilton-Dutoit,et al.  BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping , 2016, Acta oncologica.

[3]  Jeong Eon Lee,et al.  The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study , 2015, Breast Cancer Research and Treatment.

[4]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Randall W Burt,et al.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. , 2014, Diseases of the colon and rectum.

[6]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[7]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[8]  F. Muggia,et al.  'BRCAness' and its implications for platinum action in gynecologic cancer. , 2014, Anticancer research.

[9]  Rodney J Scott,et al.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database , 2013, Nature Genetics.

[10]  J. Furuse,et al.  Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805) , 2013, Cancer science.

[11]  Tom R. Gaunt,et al.  Predicting the functional consequences of cancer-associated amino acid substitutions , 2013, Bioinform..

[12]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[13]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[14]  F. Couch,et al.  Classification of missense substitutions in the BRCA genes: A database dedicated to Ex‐UVs , 2012, Human mutation.

[15]  Tao Zhang,et al.  Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population , 2011, Human mutation.

[16]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[17]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[18]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[19]  J. Mecklin,et al.  The association between cholangiooaroinoma and hereditary nonpolyposis colorectal carcinoma , 2010, Cancer.

[20]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[21]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[22]  A. Børresen-Dale,et al.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study , 2010, Human mutation.

[23]  Y. Miki,et al.  Cross‐sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer , 2008, Cancer science.

[24]  Y. Bignon,et al.  BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases , 2008, International Journal of Medical Sciences.

[25]  J. Furuse,et al.  S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study , 2008, Cancer Chemotherapy and Pharmacology.

[26]  Masahiro Yoshida,et al.  Guidelines for chemotherapy of biliary tract and ampullary carcinomas , 2008, Journal of hepato-biliary-pancreatic surgery.

[27]  M. Andreu,et al.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. , 2005, JAMA.

[28]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[29]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[30]  G. Pals,et al.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. , 1997, American journal of human genetics.

[31]  D. Easton,et al.  Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.

[32]  S. Tsuji,et al.  Mutational Analysis of BRCA1 Gene in Ovarian and Breast‐ovarian Cancer Families in Japan , 1997, Japanese journal of cancer research : Gann.

[33]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[34]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[35]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.